Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The bill directs the FDA to contract with the Reagan-Udall Foundation to convene at least four externally led, science-focused drug development (EL–SFDD) meetings per year focused on rare diseases. It requires a permanent multistakeholder steering committee, participation by FDA review-division representatives, public transcripts and summary analyses within 180 days, and annual reports to Congress on meeting topics, participation, resource impacts, and how input was used.
Progressives emphasize patient input and transparency benefits
Narrow, technical, bipartisan‑friendly subject; House may raise industry‑influence or oversight questions.
The bill directs the FDA to contract with the Reagan-Udall Foundation to convene at least four externally led, science-focused drug development (EL–SFDD) meetings per year focused on rare diseases.
It requires a permanent multistakeholder steering committee, participation by FDA review-division representatives, public transcripts and summary analyses within 180 days, and annual reports to Congress on meeting topics, participation, resource impacts, and how input was used.
The bill also requires the FDA to disclose, in approvals or licensure actions, whether relevant EL–SFDD meetings occurred and how meeting input was incorporated into risk-benefit assessments.
Narrow, administrative, and bipartisan‑amenable with modest cost increases makes enactment plausible, though appropriation and competing priorities are hurdles.
How solid the drafting looks.
Progressives emphasize patient input and transparency benefits
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize patient input and transparency benefits
Likely supportive because the bill increases patient and scientific input, transparency, and alignment on rare disease drug development.
It advances attention to unmet needs and public reporting on consensus and next steps.
Generally favorable but cautious: the bill promotes stakeholder alignment and clarity for rare disease development while creating oversight and transparency requirements.
Implementation details, resourcing, and impacts on FDA workload will determine practical value.
Skeptical: some benefits in speeding rare-disease therapies are attractive, but concerns exist about added federal spending, potential regulatory capture by industry, and creating new pathways that could pressure FDA standards.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, administrative, and bipartisan‑amenable with modest cost increases makes enactment plausible, though appropriation and competing priorities are hurdles.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize patient input and transparency benefits
Narrow, administrative, and bipartisan‑amenable with modest cost increases makes enactment plausible, though appropriation and competing pr…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Scientific EXPERT Act of 2025.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.